9/3/2021 8:03:04 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8/6/2021 8:01:47 AM
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8/5/2021 7:42:40 AM
Insmed Q2 Total Revenue $45.4 Mln Vs. $42.5 Mln Prior Year
7/8/2021 8:07:18 AM
Insmed Announces Granting Of Inducement Awards To 12 New Employees
5/11/2021 2:58:57 AM
Insmed Prices Public Offering Of 10 Mln Shares At $25/Shr And Convertible Senior Notes Due 2028
5/10/2021 7:03:28 AM
Insmed To Sell $250 Mln Of Its Common Stock
3/23/2021 5:24:37 AM
Insmed: ARIKAYCE Approved In Japan NTM Lung Disease Caused By MAC Who Did Not Respond To Prior Care With MDR
2/25/2021 8:24:28 AM
Insmed Inc Q4 Net Loss $102.2 Mln Vs. Net Loss $53.0 Mln Last Year
2/19/2021 7:31:38 AM
Insmed Announces Topline Results From Phase 1 Study Of Treprostinil Palmitil Inhalation Powder
1/4/2021 8:54:53 AM
Insmed Initiates Frontline Clinical Trial Program For ARIKAYCE In Patients With MAC Lung Disease
3/5/2008 9:54:12 AM
Collins Stewart Is Increasing Insmed Incorporated (INSM) 2008 Estimate To -0.12 From -0.16
3/5/2008 9:54:10 AM
Collins Stewart Is Increasing Insmed Incorporated (INSM) 2009 Estimate To -0.23 From -0.25